Propranolol (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Propranolol" in English language version.

refsWebsite

Global rank English rank

77nih.gov

4^th place

61doi.org

2^nd place

21semanticscholar.org

11^th place

8^th place

11web.archive.org

1^st place

4books.google.com

3^rd place

2fda.gov

447^th place

338^th place

2worldcat.org

5^th place

2clincalc.com

3,912^th place

2,496^th place

1drugbank.ca

4,294^th place

6,357^th place

1drugs.com

399^th place

333^rd place

1aappublications.org

3,763^rd place

3,602^nd place

1thieme-connect.com

low place

1tga.gov.au

3,984^th place

2,622^nd place

1handle.net

102^nd place

76^th place

1nice.org.uk

3,258^th place

2,666^th place

1sciencedirect.com

149^th place

178^th place

1thieme-connect.de

low place

1nbcnews.com

137^th place

101^st place

1dw.com

204^th place

353^rd place

1medlink.com

low place

1unc.edu

1,538^th place

1,042^nd place

1bindingdb.org

low place

1chemspider.com

8,573^rd place

low place

1independent.co.uk

36^th place

33^rd place

1theguardian.com

12^th place

11^th place

1tabletwise.com

low place

aappublications.org

pediatrics.aappublications.org

Chinnadurai S, Fonnesbeck C, Snyder KM, Sathe NA, Morad A, Likis FE, et al. (February 2016). "Pharmacologic Interventions for Infantile Hemangioma: A Meta-analysis" (PDF). Pediatrics. 137 (2): e20153896. doi:10.1542/peds.2015-3896. PMID 26772662. S2CID 30459652.

bindingdb.org

https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=25761

books.google.com

Bryson PD (1997). Comprehensive review in toxicology for emergency clinicians (3 ed.). Washington, DC: Taylor & Francis. p. 167. ISBN 9781560326120. Archived from the original on 24 March 2017.
Briggs GG, Freeman RK, Yaffe SJ (2011). Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk (9th ed.). Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins. p. 1226. ISBN 9781608317080. Archived from the original on 14 February 2017.
Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 460. ISBN 9783527607495.
Eadie M, Tyrer JH (1985). The Biochemistry of Migraine. New York: Springer. p. 148. ISBN 9780852007310. OCLC 11726870. Archived from the original on 24 March 2017.

chemspider.com

"b-Propranolol". ChemSpider. 10 June 2024. Retrieved 22 June 2025.

clincalc.com

"The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
"Propranolol Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.

doi.org

Kalam MN, Rasool MF, Rehman AU, Ahmed N (2020). "Clinical Pharmacokinetics of Propranolol Hydrochloride: A Review". Curr Drug Metab. 21 (2): 89–105. doi:10.2174/1389200221666200414094644. PMID 32286940.
Srinivasan AV (2019). "Propranolol: A 50-Year Historical Perspective". Ann Indian Acad Neurol. 22 (1): 21–26. doi:10.4103/aian.AIAN_201_18. PMC 6327687. PMID 30692755.
Davidson JR (2006). "Pharmacotherapy of social anxiety disorder: what does the evidence tell us?". The Journal of Clinical Psychiatry. 67 (Suppl 12): 20–26. doi:10.1016/j.genhosppsych.2005.07.002. PMID 17092192.
Chinnadurai S, Fonnesbeck C, Snyder KM, Sathe NA, Morad A, Likis FE, et al. (February 2016). "Pharmacologic Interventions for Infantile Hemangioma: A Meta-analysis" (PDF). Pediatrics. 137 (2): e20153896. doi:10.1542/peds.2015-3896. PMID 26772662. S2CID 30459652.
Blaisdell GD (July 1994). "Akathisia: A Comprehensive Review and Treatment Summary". Pharmacopsychiatry. 27 (4): 139–146. doi:10.1055/s-2007-1014294. ISSN 0176-3679. PMID 7972345.
James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. (February 2014). "2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)". JAMA. 311 (5): 507–520. doi:10.1001/jama.2013.284427. PMID 24352797.
Steenen SA, van Wijk AJ, van der Heijden GJ, van Westrhenen R, de Lange J, de Jongh A (February 2016). "Propranolol for the treatment of anxiety disorders: Systematic review and meta-analysis". Journal of Psychopharmacology. 30 (2): 128–139. doi:10.1177/0269881115612236. PMC 4724794. PMID 26487439.
Peggy H, Charles S (October 1987). "Beta-blockers in anxiety disorders". Journal of Affective Disorders. 13 (2): 119–130. doi:10.1016/0165-0327(87)90017-6. PMID 2890677.
Archer C, Wiles N, Kessler D, Turner K, Caldwell DM (January 2025). "Beta-blockers for the treatment of anxiety disorders: A systematic review and meta-analysis". J Affect Disord. 368: 90–99. doi:10.1016/j.jad.2024.09.068. PMID 39271062.
Steenen SA, van Wijk AJ, van der Heijden GJ, van Westrhenen R, de Lange J, de Jongh A (February 2016). "Propranolol for the treatment of anxiety disorders: Systematic review and meta-analysis". J Psychopharmacol. 30 (2): 128–139. doi:10.1177/0269881115612236. PMC 4724794. PMID 26487439.
Boyce TG, Ballone NT, Certa KM, Becker MA (2021). "The Use of β-Adrenergic Receptor Antagonists in Psychiatry: A Review". J Acad Consult Liaison Psychiatry. 62 (4): 404–412. doi:10.1016/j.jaclp.2020.12.009. PMID 34210401.
Kornischka J, Cordes J, Agelink MW (April 2007). "40 years beta-adrenoceptor blockers in psychiatry". Fortschritte der Neurologie-Psychiatrie (in German). 75 (4): 199–210. doi:10.1055/s-2006-944295. PMID 17200914. S2CID 260156607.
Vieweg V, Pandurangi A, Levenson J, Silverman J (1994). "The consulting psychiatrist and the polydipsia-hyponatremia syndrome in schizophrenia". International Journal of Psychiatry in Medicine. 24 (4): 275–303. doi:10.2190/5WG5-VV1V-BXAD-805K. PMID 7737786. S2CID 22703210.
Kishi Y, Kurosawa H, Endo S (1998). "Is propranolol effective in primary polydipsia?". International Journal of Psychiatry in Medicine. 28 (3): 315–325. doi:10.2190/QPWL-14H7-HPGG-A29D. PMID 9844835. S2CID 25222454.
Brunet A, Orr SP, Tremblay J, Robertson K, Nader K, Pitman RK (May 2008). "Effect of post-retrieval propranolol on psychophysiologic responding during subsequent script-driven traumatic imagery in post-traumatic stress disorder". Journal of Psychiatric Research. 42 (6): 503–506. doi:10.1016/j.jpsychires.2007.05.006. PMID 17588604.
Vaiva G, Ducrocq F, Jezequel K, Averland B, Lestavel P, Brunet A, et al. (November 2003). "Immediate treatment with propranolol decreases posttraumatic stress disorder two months after trauma". Biological Psychiatry. 54 (9): 947–949. doi:10.1016/s0006-3223(03)00412-8. PMID 14573324. S2CID 3064619.
Webb J (January–February 2022). "β-Blockers for the Treatment of Misophonia and Misokinesia". Clinical Neuropharmacology. 45 (1): 13–14. doi:10.1097/WNF.0000000000000492. PMID 35029865. S2CID 245932937.
Hall W, Carter A (September 2007). "Debunking alarmist objections to the pharmacological prevention of PTSD". The American Journal of Bioethics. 7 (9): 23–25. doi:10.1080/15265160701551244. PMID 17849333. S2CID 27063524.
Lima AR, Bacalcthuk J, Barnes TR, Soares-Weiser K (October 2004). "Central action beta-blockers versus placebo for neuroleptic-induced acute akathisia". The Cochrane Database of Systematic Reviews. 2004 (4): CD001946. doi:10.1002/14651858.CD001946.pub2. PMC 6599862. PMID 15495022.
Shields KG, Goadsby PJ (January 2005). "Propranolol modulates trigeminovascular responses in thalamic ventroposteromedial nucleus: a role in migraine?". Brain. 128 (Pt 1): 86–97. doi:10.1093/brain/awh298. PMID 15574468.
Chen T, Gudipudi R, Nguyen SA, Carroll W, Clemmens C (April 2022). "Should Propranolol Remain the Gold Standard for Treatment of Infantile Hemangioma? A Systematic Review and Meta-Analysis of Propranolol Versus Atenolol". The Annals of Otology, Rhinology, and Laryngology. 132 (3): 332–340. doi:10.1177/00034894221089758. PMID 35466712. S2CID 248375711.
Hogeling M (2012). "Propranolol for Infantile Hemangiomas: A Review". Current Dermatology Reports. 1 (4): Online-first. doi:10.1007/s13671-012-0026-6.
Richards JR, Albertson TE, Derlet RW, Lange RA, Olson KR, Horowitz BZ (May 2015). "Treatment of toxicity from amphetamines, related derivatives, and analogues: a systematic clinical review". Drug Alcohol Depend. 150: 1–13. doi:10.1016/j.drugalcdep.2015.01.040. PMID 25724076.
Richards JR, Hollander JE, Ramoska EA, Fareed FN, Sand IC, Izquierdo Gómez MM, et al. (May 2017). "β-Blockers, Cocaine, and the Unopposed α-Stimulation Phenomenon". J Cardiovasc Pharmacol Ther. 22 (3): 239–249. doi:10.1177/1074248416681644. PMID 28399647.
Committee on Drugs (September 2001). "Transfer of drugs and other chemicals into human milk". Pediatrics. 108 (3): 776–789. doi:10.1542/peds.108.3.776. PMID 11533352. S2CID 27763768.
Reith DM, Dawson AH, Epid D, Whyte IM, Buckley NA, Sayer GP (1996). "Relative toxicity of beta blockers in overdose". Journal of Toxicology. Clinical Toxicology. 34 (3): 273–278. doi:10.3109/15563659609013789. PMID 8667464.
Holstege CP, Eldridge DL, Rowden AK (February 2006). "ECG manifestations: the poisoned patient". Emergency Medicine Clinics of North America. 24 (1): 159–77, vii. doi:10.1016/j.emc.2005.08.012. PMID 16308118.
Maideen NM, Rajkapoor B, Muthusamy S, Ramanathan S, Thangadurai SA, Sughir AA (2021). "A Review on Pharmacokinetic and Pharmacodynamic Drug Interactions of Adrenergic β-blockers with Clinically Relevant Drugs-An Overview". Curr Drug Metab. 22 (9): 672–682. doi:10.2174/1389200222666210614112529. PMID 34182907.
Shin J, Hills NK, Finley PR (June 2020). "Combining Antidepressants with β-Blockers: Evidence of a Clinically Significant CYP2D6 Drug Interaction". Pharmacotherapy. 40 (6): 507–516. doi:10.1002/phar.2406. PMID 32342526.
Zhou SF (2009). "Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I". Clin Pharmacokinet. 48 (11): 689–723. doi:10.2165/11318030-000000000-00000. PMID 19817501.
van Harten J (1995). "Overview of the pharmacokinetics of fluvoxamine". Clinical Pharmacokinetics. 29 (Suppl 1): 1–9. doi:10.2165/00003088-199500291-00003. PMID 8846617. S2CID 71812133.
Tsuchihashi H, Nakashima Y, Kinami J, Nagatomo T (February 1990). "Characteristics of 125I-iodocyanopindolol binding to beta-adrenergic and serotonin-1B receptors of rat brain: selectivity of beta-adrenergic agents". Japanese Journal of Pharmacology. 52 (2): 195–200. doi:10.1254/jjp.52.195. PMID 1968985.
Engel G, Göthert M, Hoyer D, Schlicker E, Hillenbrand K (January 1986). "Identity of inhibitory presynaptic 5-hydroxytryptamine (5-HT) autoreceptors in the rat brain cortex with 5-HT1B binding sites". Naunyn-Schmiedeberg's Archives of Pharmacology. 332 (1): 1–7. doi:10.1007/bf00633189. PMID 2936965. S2CID 5999838.
Schlicker E, Fink K, Göthert M, Hoyer D, Molderings G, Roschke I, et al. (July 1989). "The pharmacological properties of the presynaptic serotonin autoreceptor in the pig brain cortex conform to the 5-HT1D receptor subtype". Naunyn-Schmiedeberg's Archives of Pharmacology. 340 (1): 45–51. doi:10.1007/bf00169206. PMID 2797214. S2CID 2287040.
Elliott JM, Kent A (July 1989). "Comparison of [125I]iodolysergic acid diethylamide binding in human frontal cortex and platelet tissue". Journal of Neurochemistry. 53 (1): 191–196. doi:10.1111/j.1471-4159.1989.tb07313.x. PMID 2723656. S2CID 25820829.
Schmuck K, Ullmer C, Kalkman HO, Probst A, Lubbert H (May 1996). "Activation of meningeal 5-HT2B receptors: an early step in the generation of migraine headache?". The European Journal of Neuroscience. 8 (5): 959–967. doi:10.1111/j.1460-9568.1996.tb01583.x. PMID 8743744. S2CID 19578349.
Yagaloff KA, Hartig PR (December 1985). "125I-lysergic acid diethylamide binds to a novel serotonergic site on rat choroid plexus epithelial cells". The Journal of Neuroscience. 5 (12): 3178–3183. doi:10.1523/JNEUROSCI.05-12-03178.1985. PMC 6565215. PMID 4078623.
Barnes JM, Barnes NM, Costall B, Ironside JW, Naylor RJ (December 1989). "Identification and characterisation of 5-hydroxytryptamine 3 recognition sites in human brain tissue". Journal of Neurochemistry. 53 (6): 1787–1793. doi:10.1111/j.1471-4159.1989.tb09244.x. PMID 2809591. S2CID 46356673.
Boyajian CL, Leslie FM (June 1987). "Pharmacological evidence for alpha-2 adrenoceptor heterogeneity: differential binding properties of [3H]rauwolscine and [3H]idazoxan in rat brain". The Journal of Pharmacology and Experimental Therapeutics. 241 (3): 1092–1098. doi:10.1016/S0022-5347(25)00190-9. PMID 2885406.
Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, et al. (March 1996). "Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding". Psychopharmacology. 124 (1–2): 57–73. doi:10.1007/bf02245606. PMID 8935801. S2CID 12028979.
Fraundorfer PF, Fertel RH, Miller DD, Feller DR (August 1994). "Biochemical and pharmacological characterization of high-affinity trimetoquinol analogs on guinea pig and human beta adrenergic receptor subtypes: evidence for partial agonism". The Journal of Pharmacology and Experimental Therapeutics. 270 (2): 665–674. doi:10.1016/S0022-3565(25)22397-7. PMID 7915318.
Nahmias C, Blin N, Elalouf JM, Mattei MG, Strosberg AD, Emorine LJ (December 1991). "Molecular characterization of the mouse beta 3-adrenergic receptor: relationship with the atypical receptor of adipocytes". The EMBO Journal. 10 (12): 3721–3727. doi:10.1002/j.1460-2075.1991.tb04940.x. PMC 453106. PMID 1718744.
Kanba S, Richelson E (June 1984). "Histamine H1 receptors in human brain labelled with [3H]doxepin". Brain Research. 304 (1): 1–7. doi:10.1016/0006-8993(84)90856-4. PMID 6146381. S2CID 45303586.
Kovachich GB, Aronson CE, Brunswick DJ, Frazer A (June 1988). "Quantitative autoradiography of serotonin uptake sites in rat brain using [3H]cyanoimipramine". Brain Research. 454 (1–2): 78–88. doi:10.1016/0006-8993(88)90805-0. PMID 2970277. S2CID 9586842.
Tuross N, Patrick RL (June 1986). "Effects of propranolol on catecholamine synthesis and uptake in the central nervous system of the rat". The Journal of Pharmacology and Experimental Therapeutics. 237 (3): 739–745. doi:10.1016/S0022-3565(25)24861-3. PMID 2872325.
Zobrist RH, Mecca TE (May 1990). "[3H]TA-3090, a selective benzothiazepine-type calcium channel receptor antagonist: in vitro characterization". The Journal of Pharmacology and Experimental Therapeutics. 253 (2): 461–465. doi:10.1016/S0022-3565(25)12990-X. PMID 2338642.
Al-Majed AA, Bakheit AH, Abdel Aziz HA, Alajmi FM, AlRabiah H (2017). Propranolol. Profiles of Drug Substances, Excipients and Related Methodology. Vol. 42. pp. 287–338. doi:10.1016/bs.podrm.2017.02.006. ISBN 9780128122266. PMID 28431779. {{cite book}}: |journal= ignored (help)
Young R, Glennon RA (April 2009). "S(-)Propranolol as a discriminative stimulus and its comparison to the stimulus effects of cocaine in rats". Psychopharmacology. 203 (2): 369–382. doi:10.1007/s00213-008-1317-2. PMID 18795268.
Glennon RA (January 1987). "Central serotonin receptors as targets for drug research". J Med Chem. 30 (1): 1–12. doi:10.1021/jm00384a001. PMID 3543362. Table II. Affinities of Selected Phenalkylamines for 5-HT1 and 5-HT2 Binding Sites
Davids E, Lesch KP (November 1996). "[The 5-HT1A receptor: a new effective principle in psychopharmacologic therapy?]". Fortschritte der Neurologie-Psychiatrie (in German). 64 (11): 460–472. doi:10.1055/s-2007-996592. PMID 9064274. S2CID 147793142.
Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, et al. (June 1994). "International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin)". Pharmacological Reviews. 46 (2): 157–203. doi:10.1016/S0031-6997(25)06783-3. PMID 7938165.
Wang DW, Mistry AM, Kahlig KM, Kearney JA, Xiang J, George AL (2010). "Propranolol blocks cardiac and neuronal voltage-gated sodium channels". Frontiers in Pharmacology. 1: 144. doi:10.3389/fphar.2010.00144. PMC 3153018. PMID 21833183.
Bankston JR, Kass RS (January 2010). "Molecular determinants of local anesthetic action of beta-blocking drugs: Implications for therapeutic management of long QT syndrome variant 3". Journal of Molecular and Cellular Cardiology. 48 (1): 246–253. doi:10.1016/j.yjmcc.2009.05.012. PMC 2813422. PMID 19481549.
Desaphy JF, Pierno S, De Luca A, Didonna P, Camerino DC (March 2003). "Different ability of clenbuterol and salbutamol to block sodium channels predicts their therapeutic use in muscle excitability disorders" (PDF). Molecular Pharmacology. 63 (3): 659–670. doi:10.1124/mol.63.3.659. PMID 12606775. S2CID 631197. Archived from the original (PDF) on 20 February 2019.
Nagare N, Damre A, Singh KS, Mallurwar SR, Iyer S, Naik A, et al. (September 2010). "Determination of site of absorption of propranolol in rat gut using in situ single-pass intestinal perfusion". Indian Journal of Pharmaceutical Sciences. 72 (5): 625–629. doi:10.4103/0250-474X.78533. PMC 3116309. PMID 21694996.
Heel RC, Brogden RN, Speight TM, Avery GS (June 1979). "Atenolol: a review of its pharmacological properties and therapeutic efficacy in angina pectoris and hypertension". Drugs. 17 (6): 425–460. doi:10.2165/00003495-197917060-00001. PMID 38096.
Tekes K, Szegi P, Hashemi F, Laufer R, Kalász H, Siddiq A, et al. (2013). "Medicinal chemistry of antimigraine drugs". Curr Med Chem. 20 (26): 3300–3316. doi:10.2174/0929867311320260012. PMID 23746273.
Black JW, Crowther AF, Shanks RG, Smith LH, Dornhorst AC (May 1964). "A New Adrenergic Beta-Receptor Antagonist". Lancet. 1 (7342): 1080–1081. doi:10.1016/S0140-6736(64)91275-9. PMID 14132613.
Steptoe A, Malik F, Pay C, Pearson P, Price C, Win Z (1995). "The impact of stage fright on student actors". Br J Psychol. 86: 27–39. doi:10.1111/j.2044-8295.1995.tb02544.x.
Lockwood AH (January 1989). "Medical problems of musicians". The New England Journal of Medicine. 320 (4): 221–227. doi:10.1056/nejm198901263200405. PMID 2643048.
Quirke V (January 2006). "Putting theory into practice: James Black, receptor theory and the development of the beta-blockers at ICI, 1958-1978". Med Hist. 50 (1): 69–92. doi:10.1017/s0025727300009455. PMC 1369014. PMID 16502872.

drugbank.ca

"Propranolol". www.drugbank.ca. Retrieved 31 January 2019.

drugs.com

"Propranolol hydrochloride". Monograph. The American Society of Health-System Pharmacists. Archived from the original on 1 January 2015. Retrieved 1 January 2015.

dw.com

"DocFilm – DW". dw.com. Retrieved 2 August 2023.

fda.gov

accessdata.fda.gov

https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/016418s080,016762s017,017683s008lbl.pdf
"Hemangeol - Food and Drug Administration" (PDF). 1 March 2014. Archived (PDF) from the original on 2 April 2015. Retrieved 23 March 2015.

handle.net

hdl.handle.net

World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

independent.co.uk

Tim Glover. "Golf: O'Grady says players use beta-blockers: Drugs 'helped win majors'". The Independent. Archived from the original on 25 September 2015. Retrieved 28 March 2017.

medlink.com

Chan C, Goadsby PJ (26 September 1996). Silberstein SD (ed.). "Primary exercise headache". MedLink.

nbcnews.com

"Doctors test a drug to ease traumatic memories - Mental Health - NBC News". NBC News. Archived from the original on 12 November 2013. Retrieved 30 June 2007.

nice.org.uk

Ladva S (28 June 2006). "NICE and BHS launch updated hypertension guideline". National Institute for Health and Clinical Excellence. Archived from the original on 24 September 2006. Retrieved 11 October 2009.

nih.gov

pubmed.ncbi.nlm.nih.gov

Kalam MN, Rasool MF, Rehman AU, Ahmed N (2020). "Clinical Pharmacokinetics of Propranolol Hydrochloride: A Review". Curr Drug Metab. 21 (2): 89–105. doi:10.2174/1389200221666200414094644. PMID 32286940.
Srinivasan AV (2019). "Propranolol: A 50-Year Historical Perspective". Ann Indian Acad Neurol. 22 (1): 21–26. doi:10.4103/aian.AIAN_201_18. PMC 6327687. PMID 30692755.
Davidson JR (2006). "Pharmacotherapy of social anxiety disorder: what does the evidence tell us?". The Journal of Clinical Psychiatry. 67 (Suppl 12): 20–26. doi:10.1016/j.genhosppsych.2005.07.002. PMID 17092192.
Chinnadurai S, Fonnesbeck C, Snyder KM, Sathe NA, Morad A, Likis FE, et al. (February 2016). "Pharmacologic Interventions for Infantile Hemangioma: A Meta-analysis" (PDF). Pediatrics. 137 (2): e20153896. doi:10.1542/peds.2015-3896. PMID 26772662. S2CID 30459652.
Blaisdell GD (July 1994). "Akathisia: A Comprehensive Review and Treatment Summary". Pharmacopsychiatry. 27 (4): 139–146. doi:10.1055/s-2007-1014294. ISSN 0176-3679. PMID 7972345.
James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. (February 2014). "2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)". JAMA. 311 (5): 507–520. doi:10.1001/jama.2013.284427. PMID 24352797.
Steenen SA, van Wijk AJ, van der Heijden GJ, van Westrhenen R, de Lange J, de Jongh A (February 2016). "Propranolol for the treatment of anxiety disorders: Systematic review and meta-analysis". Journal of Psychopharmacology. 30 (2): 128–139. doi:10.1177/0269881115612236. PMC 4724794. PMID 26487439.
Peggy H, Charles S (October 1987). "Beta-blockers in anxiety disorders". Journal of Affective Disorders. 13 (2): 119–130. doi:10.1016/0165-0327(87)90017-6. PMID 2890677.
Archer C, Wiles N, Kessler D, Turner K, Caldwell DM (January 2025). "Beta-blockers for the treatment of anxiety disorders: A systematic review and meta-analysis". J Affect Disord. 368: 90–99. doi:10.1016/j.jad.2024.09.068. PMID 39271062.
Steenen SA, van Wijk AJ, van der Heijden GJ, van Westrhenen R, de Lange J, de Jongh A (February 2016). "Propranolol for the treatment of anxiety disorders: Systematic review and meta-analysis". J Psychopharmacol. 30 (2): 128–139. doi:10.1177/0269881115612236. PMC 4724794. PMID 26487439.
Boyce TG, Ballone NT, Certa KM, Becker MA (2021). "The Use of β-Adrenergic Receptor Antagonists in Psychiatry: A Review". J Acad Consult Liaison Psychiatry. 62 (4): 404–412. doi:10.1016/j.jaclp.2020.12.009. PMID 34210401.
Kornischka J, Cordes J, Agelink MW (April 2007). "40 years beta-adrenoceptor blockers in psychiatry". Fortschritte der Neurologie-Psychiatrie (in German). 75 (4): 199–210. doi:10.1055/s-2006-944295. PMID 17200914. S2CID 260156607.
Thibaut F, Colonna L (1993). "[Anti-aggressive effect of beta-blockers]". L'Encephale (in French). 19 (3): 263–267. PMID 7903928.
Vieweg V, Pandurangi A, Levenson J, Silverman J (1994). "The consulting psychiatrist and the polydipsia-hyponatremia syndrome in schizophrenia". International Journal of Psychiatry in Medicine. 24 (4): 275–303. doi:10.2190/5WG5-VV1V-BXAD-805K. PMID 7737786. S2CID 22703210.
Kishi Y, Kurosawa H, Endo S (1998). "Is propranolol effective in primary polydipsia?". International Journal of Psychiatry in Medicine. 28 (3): 315–325. doi:10.2190/QPWL-14H7-HPGG-A29D. PMID 9844835. S2CID 25222454.
Brunet A, Orr SP, Tremblay J, Robertson K, Nader K, Pitman RK (May 2008). "Effect of post-retrieval propranolol on psychophysiologic responding during subsequent script-driven traumatic imagery in post-traumatic stress disorder". Journal of Psychiatric Research. 42 (6): 503–506. doi:10.1016/j.jpsychires.2007.05.006. PMID 17588604.
Young C, Butcher R (2020). Propranolol for Post-Traumatic Stress Disorder: A Review of Clinical Effectiveness. CADTH Rapid Response Reports. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health. PMID 33074615.
Vaiva G, Ducrocq F, Jezequel K, Averland B, Lestavel P, Brunet A, et al. (November 2003). "Immediate treatment with propranolol decreases posttraumatic stress disorder two months after trauma". Biological Psychiatry. 54 (9): 947–949. doi:10.1016/s0006-3223(03)00412-8. PMID 14573324. S2CID 3064619.
Webb J (January–February 2022). "β-Blockers for the Treatment of Misophonia and Misokinesia". Clinical Neuropharmacology. 45 (1): 13–14. doi:10.1097/WNF.0000000000000492. PMID 35029865. S2CID 245932937.
Hall W, Carter A (September 2007). "Debunking alarmist objections to the pharmacological prevention of PTSD". The American Journal of Bioethics. 7 (9): 23–25. doi:10.1080/15265160701551244. PMID 17849333. S2CID 27063524.
Lima AR, Bacalcthuk J, Barnes TR, Soares-Weiser K (October 2004). "Central action beta-blockers versus placebo for neuroleptic-induced acute akathisia". The Cochrane Database of Systematic Reviews. 2004 (4): CD001946. doi:10.1002/14651858.CD001946.pub2. PMC 6599862. PMID 15495022.
Shields KG, Goadsby PJ (January 2005). "Propranolol modulates trigeminovascular responses in thalamic ventroposteromedial nucleus: a role in migraine?". Brain. 128 (Pt 1): 86–97. doi:10.1093/brain/awh298. PMID 15574468.
Chen T, Gudipudi R, Nguyen SA, Carroll W, Clemmens C (April 2022). "Should Propranolol Remain the Gold Standard for Treatment of Infantile Hemangioma? A Systematic Review and Meta-Analysis of Propranolol Versus Atenolol". The Annals of Otology, Rhinology, and Laryngology. 132 (3): 332–340. doi:10.1177/00034894221089758. PMID 35466712. S2CID 248375711.
Richards JR, Albertson TE, Derlet RW, Lange RA, Olson KR, Horowitz BZ (May 2015). "Treatment of toxicity from amphetamines, related derivatives, and analogues: a systematic clinical review". Drug Alcohol Depend. 150: 1–13. doi:10.1016/j.drugalcdep.2015.01.040. PMID 25724076.
Richards JR, Hollander JE, Ramoska EA, Fareed FN, Sand IC, Izquierdo Gómez MM, et al. (May 2017). "β-Blockers, Cocaine, and the Unopposed α-Stimulation Phenomenon". J Cardiovasc Pharmacol Ther. 22 (3): 239–249. doi:10.1177/1074248416681644. PMID 28399647.
Committee on Drugs (September 2001). "Transfer of drugs and other chemicals into human milk". Pediatrics. 108 (3): 776–789. doi:10.1542/peds.108.3.776. PMID 11533352. S2CID 27763768.
Spencer JP, Gonzalez LS, Barnhart DJ (July 2001). "Medications in the breast-feeding mother". American Family Physician. 64 (1): 119–126. PMID 11456429.
Reith DM, Dawson AH, Epid D, Whyte IM, Buckley NA, Sayer GP (1996). "Relative toxicity of beta blockers in overdose". Journal of Toxicology. Clinical Toxicology. 34 (3): 273–278. doi:10.3109/15563659609013789. PMID 8667464.
Holstege CP, Eldridge DL, Rowden AK (February 2006). "ECG manifestations: the poisoned patient". Emergency Medicine Clinics of North America. 24 (1): 159–77, vii. doi:10.1016/j.emc.2005.08.012. PMID 16308118.
Maideen NM, Rajkapoor B, Muthusamy S, Ramanathan S, Thangadurai SA, Sughir AA (2021). "A Review on Pharmacokinetic and Pharmacodynamic Drug Interactions of Adrenergic β-blockers with Clinically Relevant Drugs-An Overview". Curr Drug Metab. 22 (9): 672–682. doi:10.2174/1389200222666210614112529. PMID 34182907.
Shin J, Hills NK, Finley PR (June 2020). "Combining Antidepressants with β-Blockers: Evidence of a Clinically Significant CYP2D6 Drug Interaction". Pharmacotherapy. 40 (6): 507–516. doi:10.1002/phar.2406. PMID 32342526.
Zhou SF (2009). "Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I". Clin Pharmacokinet. 48 (11): 689–723. doi:10.2165/11318030-000000000-00000. PMID 19817501.
van Harten J (1995). "Overview of the pharmacokinetics of fluvoxamine". Clinical Pharmacokinetics. 29 (Suppl 1): 1–9. doi:10.2165/00003088-199500291-00003. PMID 8846617. S2CID 71812133.
Hamon M, Lanfumey L, el Mestikawy S, Boni C, Miquel MC, Bolaños F, et al. (1990). "The main features of central 5-HT1 receptors". Neuropsychopharmacology. 3 (5–6): 349–360. PMID 2078271.
Toll L, Berzetei-Gurske IP, Polgar WE, Brandt SR, Adapa ID, Rodriguez L, et al. (March 1998). "Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications". NIDA Research Monograph. 178: 440–466. PMID 9686407.
Tsuchihashi H, Nakashima Y, Kinami J, Nagatomo T (February 1990). "Characteristics of 125I-iodocyanopindolol binding to beta-adrenergic and serotonin-1B receptors of rat brain: selectivity of beta-adrenergic agents". Japanese Journal of Pharmacology. 52 (2): 195–200. doi:10.1254/jjp.52.195. PMID 1968985.
Engel G, Göthert M, Hoyer D, Schlicker E, Hillenbrand K (January 1986). "Identity of inhibitory presynaptic 5-hydroxytryptamine (5-HT) autoreceptors in the rat brain cortex with 5-HT1B binding sites". Naunyn-Schmiedeberg's Archives of Pharmacology. 332 (1): 1–7. doi:10.1007/bf00633189. PMID 2936965. S2CID 5999838.
Schlicker E, Fink K, Göthert M, Hoyer D, Molderings G, Roschke I, et al. (July 1989). "The pharmacological properties of the presynaptic serotonin autoreceptor in the pig brain cortex conform to the 5-HT1D receptor subtype". Naunyn-Schmiedeberg's Archives of Pharmacology. 340 (1): 45–51. doi:10.1007/bf00169206. PMID 2797214. S2CID 2287040.
Elliott JM, Kent A (July 1989). "Comparison of [125I]iodolysergic acid diethylamide binding in human frontal cortex and platelet tissue". Journal of Neurochemistry. 53 (1): 191–196. doi:10.1111/j.1471-4159.1989.tb07313.x. PMID 2723656. S2CID 25820829.
Schmuck K, Ullmer C, Kalkman HO, Probst A, Lubbert H (May 1996). "Activation of meningeal 5-HT2B receptors: an early step in the generation of migraine headache?". The European Journal of Neuroscience. 8 (5): 959–967. doi:10.1111/j.1460-9568.1996.tb01583.x. PMID 8743744. S2CID 19578349.
Yagaloff KA, Hartig PR (December 1985). "125I-lysergic acid diethylamide binds to a novel serotonergic site on rat choroid plexus epithelial cells". The Journal of Neuroscience. 5 (12): 3178–3183. doi:10.1523/JNEUROSCI.05-12-03178.1985. PMC 6565215. PMID 4078623.
Barnes JM, Barnes NM, Costall B, Ironside JW, Naylor RJ (December 1989). "Identification and characterisation of 5-hydroxytryptamine 3 recognition sites in human brain tissue". Journal of Neurochemistry. 53 (6): 1787–1793. doi:10.1111/j.1471-4159.1989.tb09244.x. PMID 2809591. S2CID 46356673.
Boyajian CL, Leslie FM (June 1987). "Pharmacological evidence for alpha-2 adrenoceptor heterogeneity: differential binding properties of [3H]rauwolscine and [3H]idazoxan in rat brain". The Journal of Pharmacology and Experimental Therapeutics. 241 (3): 1092–1098. doi:10.1016/S0022-5347(25)00190-9. PMID 2885406.
Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, et al. (March 1996). "Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding". Psychopharmacology. 124 (1–2): 57–73. doi:10.1007/bf02245606. PMID 8935801. S2CID 12028979.
Fraundorfer PF, Fertel RH, Miller DD, Feller DR (August 1994). "Biochemical and pharmacological characterization of high-affinity trimetoquinol analogs on guinea pig and human beta adrenergic receptor subtypes: evidence for partial agonism". The Journal of Pharmacology and Experimental Therapeutics. 270 (2): 665–674. doi:10.1016/S0022-3565(25)22397-7. PMID 7915318.
Nahmias C, Blin N, Elalouf JM, Mattei MG, Strosberg AD, Emorine LJ (December 1991). "Molecular characterization of the mouse beta 3-adrenergic receptor: relationship with the atypical receptor of adipocytes". The EMBO Journal. 10 (12): 3721–3727. doi:10.1002/j.1460-2075.1991.tb04940.x. PMC 453106. PMID 1718744.
Kanba S, Richelson E (June 1984). "Histamine H1 receptors in human brain labelled with [3H]doxepin". Brain Research. 304 (1): 1–7. doi:10.1016/0006-8993(84)90856-4. PMID 6146381. S2CID 45303586.
Kovachich GB, Aronson CE, Brunswick DJ, Frazer A (June 1988). "Quantitative autoradiography of serotonin uptake sites in rat brain using [3H]cyanoimipramine". Brain Research. 454 (1–2): 78–88. doi:10.1016/0006-8993(88)90805-0. PMID 2970277. S2CID 9586842.
Tuross N, Patrick RL (June 1986). "Effects of propranolol on catecholamine synthesis and uptake in the central nervous system of the rat". The Journal of Pharmacology and Experimental Therapeutics. 237 (3): 739–745. doi:10.1016/S0022-3565(25)24861-3. PMID 2872325.
Zobrist RH, Mecca TE (May 1990). "[3H]TA-3090, a selective benzothiazepine-type calcium channel receptor antagonist: in vitro characterization". The Journal of Pharmacology and Experimental Therapeutics. 253 (2): 461–465. doi:10.1016/S0022-3565(25)12990-X. PMID 2338642.
Al-Majed AA, Bakheit AH, Abdel Aziz HA, Alajmi FM, AlRabiah H (2017). Propranolol. Profiles of Drug Substances, Excipients and Related Methodology. Vol. 42. pp. 287–338. doi:10.1016/bs.podrm.2017.02.006. ISBN 9780128122266. PMID 28431779. {{cite book}}: |journal= ignored (help)
Young R, Glennon RA (April 2009). "S(-)Propranolol as a discriminative stimulus and its comparison to the stimulus effects of cocaine in rats". Psychopharmacology. 203 (2): 369–382. doi:10.1007/s00213-008-1317-2. PMID 18795268.
Glennon RA (January 1987). "Central serotonin receptors as targets for drug research". J Med Chem. 30 (1): 1–12. doi:10.1021/jm00384a001. PMID 3543362. Table II. Affinities of Selected Phenalkylamines for 5-HT1 and 5-HT2 Binding Sites
Davids E, Lesch KP (November 1996). "[The 5-HT1A receptor: a new effective principle in psychopharmacologic therapy?]". Fortschritte der Neurologie-Psychiatrie (in German). 64 (11): 460–472. doi:10.1055/s-2007-996592. PMID 9064274. S2CID 147793142.
Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, et al. (June 1994). "International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin)". Pharmacological Reviews. 46 (2): 157–203. doi:10.1016/S0031-6997(25)06783-3. PMID 7938165.
Wang DW, Mistry AM, Kahlig KM, Kearney JA, Xiang J, George AL (2010). "Propranolol blocks cardiac and neuronal voltage-gated sodium channels". Frontiers in Pharmacology. 1: 144. doi:10.3389/fphar.2010.00144. PMC 3153018. PMID 21833183.
Bankston JR, Kass RS (January 2010). "Molecular determinants of local anesthetic action of beta-blocking drugs: Implications for therapeutic management of long QT syndrome variant 3". Journal of Molecular and Cellular Cardiology. 48 (1): 246–253. doi:10.1016/j.yjmcc.2009.05.012. PMC 2813422. PMID 19481549.
Desaphy JF, Pierno S, De Luca A, Didonna P, Camerino DC (March 2003). "Different ability of clenbuterol and salbutamol to block sodium channels predicts their therapeutic use in muscle excitability disorders" (PDF). Molecular Pharmacology. 63 (3): 659–670. doi:10.1124/mol.63.3.659. PMID 12606775. S2CID 631197. Archived from the original (PDF) on 20 February 2019.
Nagare N, Damre A, Singh KS, Mallurwar SR, Iyer S, Naik A, et al. (September 2010). "Determination of site of absorption of propranolol in rat gut using in situ single-pass intestinal perfusion". Indian Journal of Pharmaceutical Sciences. 72 (5): 625–629. doi:10.4103/0250-474X.78533. PMC 3116309. PMID 21694996.
Shand DG (1976). "Pharmacokinetics of propranolol: a review". Postgrad Med J. 52 Suppl 4: 22–25. PMID 787953.
Heel RC, Brogden RN, Speight TM, Avery GS (June 1979). "Atenolol: a review of its pharmacological properties and therapeutic efficacy in angina pectoris and hypertension". Drugs. 17 (6): 425–460. doi:10.2165/00003495-197917060-00001. PMID 38096.
Tekes K, Szegi P, Hashemi F, Laufer R, Kalász H, Siddiq A, et al. (2013). "Medicinal chemistry of antimigraine drugs". Curr Med Chem. 20 (26): 3300–3316. doi:10.2174/0929867311320260012. PMID 23746273.
Black JW, Crowther AF, Shanks RG, Smith LH, Dornhorst AC (May 1964). "A New Adrenergic Beta-Receptor Antagonist". Lancet. 1 (7342): 1080–1081. doi:10.1016/S0140-6736(64)91275-9. PMID 14132613.
Lockwood AH (January 1989). "Medical problems of musicians". The New England Journal of Medicine. 320 (4): 221–227. doi:10.1056/nejm198901263200405. PMID 2643048.
Quirke V (January 2006). "Putting theory into practice: James Black, receptor theory and the development of the beta-blockers at ICI, 1958-1978". Med Hist. 50 (1): 69–92. doi:10.1017/s0025727300009455. PMC 1369014. PMID 16502872.

ncbi.nlm.nih.gov

Srinivasan AV (2019). "Propranolol: A 50-Year Historical Perspective". Ann Indian Acad Neurol. 22 (1): 21–26. doi:10.4103/aian.AIAN_201_18. PMC 6327687. PMID 30692755.
Steenen SA, van Wijk AJ, van der Heijden GJ, van Westrhenen R, de Lange J, de Jongh A (February 2016). "Propranolol for the treatment of anxiety disorders: Systematic review and meta-analysis". Journal of Psychopharmacology. 30 (2): 128–139. doi:10.1177/0269881115612236. PMC 4724794. PMID 26487439.
Steenen SA, van Wijk AJ, van der Heijden GJ, van Westrhenen R, de Lange J, de Jongh A (February 2016). "Propranolol for the treatment of anxiety disorders: Systematic review and meta-analysis". J Psychopharmacol. 30 (2): 128–139. doi:10.1177/0269881115612236. PMC 4724794. PMID 26487439.
Young C, Butcher R (2020). Propranolol for Post-Traumatic Stress Disorder: A Review of Clinical Effectiveness. CADTH Rapid Response Reports. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health. PMID 33074615.
Lima AR, Bacalcthuk J, Barnes TR, Soares-Weiser K (October 2004). "Central action beta-blockers versus placebo for neuroleptic-induced acute akathisia". The Cochrane Database of Systematic Reviews. 2004 (4): CD001946. doi:10.1002/14651858.CD001946.pub2. PMC 6599862. PMID 15495022.
Yagaloff KA, Hartig PR (December 1985). "125I-lysergic acid diethylamide binds to a novel serotonergic site on rat choroid plexus epithelial cells". The Journal of Neuroscience. 5 (12): 3178–3183. doi:10.1523/JNEUROSCI.05-12-03178.1985. PMC 6565215. PMID 4078623.
Nahmias C, Blin N, Elalouf JM, Mattei MG, Strosberg AD, Emorine LJ (December 1991). "Molecular characterization of the mouse beta 3-adrenergic receptor: relationship with the atypical receptor of adipocytes". The EMBO Journal. 10 (12): 3721–3727. doi:10.1002/j.1460-2075.1991.tb04940.x. PMC 453106. PMID 1718744.
Wang DW, Mistry AM, Kahlig KM, Kearney JA, Xiang J, George AL (2010). "Propranolol blocks cardiac and neuronal voltage-gated sodium channels". Frontiers in Pharmacology. 1: 144. doi:10.3389/fphar.2010.00144. PMC 3153018. PMID 21833183.
Bankston JR, Kass RS (January 2010). "Molecular determinants of local anesthetic action of beta-blocking drugs: Implications for therapeutic management of long QT syndrome variant 3". Journal of Molecular and Cellular Cardiology. 48 (1): 246–253. doi:10.1016/j.yjmcc.2009.05.012. PMC 2813422. PMID 19481549.
Nagare N, Damre A, Singh KS, Mallurwar SR, Iyer S, Naik A, et al. (September 2010). "Determination of site of absorption of propranolol in rat gut using in situ single-pass intestinal perfusion". Indian Journal of Pharmaceutical Sciences. 72 (5): 625–629. doi:10.4103/0250-474X.78533. PMC 3116309. PMID 21694996.
Quirke V (January 2006). "Putting theory into practice: James Black, receptor theory and the development of the beta-blockers at ICI, 1958-1978". Med Hist. 50 (1): 69–92. doi:10.1017/s0025727300009455. PMC 1369014. PMID 16502872.

pubchem.ncbi.nlm.nih.gov

"Propranolol". pubchem.ncbi.nlm.nih.gov. Retrieved 31 January 2019.

sciencedirect.com

Peggy H, Charles S (October 1987). "Beta-blockers in anxiety disorders". Journal of Affective Disorders. 13 (2): 119–130. doi:10.1016/0165-0327(87)90017-6. PMID 2890677.

semanticscholar.org

api.semanticscholar.org

Chinnadurai S, Fonnesbeck C, Snyder KM, Sathe NA, Morad A, Likis FE, et al. (February 2016). "Pharmacologic Interventions for Infantile Hemangioma: A Meta-analysis" (PDF). Pediatrics. 137 (2): e20153896. doi:10.1542/peds.2015-3896. PMID 26772662. S2CID 30459652.
Kornischka J, Cordes J, Agelink MW (April 2007). "40 years beta-adrenoceptor blockers in psychiatry". Fortschritte der Neurologie-Psychiatrie (in German). 75 (4): 199–210. doi:10.1055/s-2006-944295. PMID 17200914. S2CID 260156607.
Vieweg V, Pandurangi A, Levenson J, Silverman J (1994). "The consulting psychiatrist and the polydipsia-hyponatremia syndrome in schizophrenia". International Journal of Psychiatry in Medicine. 24 (4): 275–303. doi:10.2190/5WG5-VV1V-BXAD-805K. PMID 7737786. S2CID 22703210.
Kishi Y, Kurosawa H, Endo S (1998). "Is propranolol effective in primary polydipsia?". International Journal of Psychiatry in Medicine. 28 (3): 315–325. doi:10.2190/QPWL-14H7-HPGG-A29D. PMID 9844835. S2CID 25222454.
Vaiva G, Ducrocq F, Jezequel K, Averland B, Lestavel P, Brunet A, et al. (November 2003). "Immediate treatment with propranolol decreases posttraumatic stress disorder two months after trauma". Biological Psychiatry. 54 (9): 947–949. doi:10.1016/s0006-3223(03)00412-8. PMID 14573324. S2CID 3064619.
Webb J (January–February 2022). "β-Blockers for the Treatment of Misophonia and Misokinesia". Clinical Neuropharmacology. 45 (1): 13–14. doi:10.1097/WNF.0000000000000492. PMID 35029865. S2CID 245932937.
Hall W, Carter A (September 2007). "Debunking alarmist objections to the pharmacological prevention of PTSD". The American Journal of Bioethics. 7 (9): 23–25. doi:10.1080/15265160701551244. PMID 17849333. S2CID 27063524.
Chen T, Gudipudi R, Nguyen SA, Carroll W, Clemmens C (April 2022). "Should Propranolol Remain the Gold Standard for Treatment of Infantile Hemangioma? A Systematic Review and Meta-Analysis of Propranolol Versus Atenolol". The Annals of Otology, Rhinology, and Laryngology. 132 (3): 332–340. doi:10.1177/00034894221089758. PMID 35466712. S2CID 248375711.
Committee on Drugs (September 2001). "Transfer of drugs and other chemicals into human milk". Pediatrics. 108 (3): 776–789. doi:10.1542/peds.108.3.776. PMID 11533352. S2CID 27763768.
van Harten J (1995). "Overview of the pharmacokinetics of fluvoxamine". Clinical Pharmacokinetics. 29 (Suppl 1): 1–9. doi:10.2165/00003088-199500291-00003. PMID 8846617. S2CID 71812133.
Engel G, Göthert M, Hoyer D, Schlicker E, Hillenbrand K (January 1986). "Identity of inhibitory presynaptic 5-hydroxytryptamine (5-HT) autoreceptors in the rat brain cortex with 5-HT1B binding sites". Naunyn-Schmiedeberg's Archives of Pharmacology. 332 (1): 1–7. doi:10.1007/bf00633189. PMID 2936965. S2CID 5999838.
Schlicker E, Fink K, Göthert M, Hoyer D, Molderings G, Roschke I, et al. (July 1989). "The pharmacological properties of the presynaptic serotonin autoreceptor in the pig brain cortex conform to the 5-HT1D receptor subtype". Naunyn-Schmiedeberg's Archives of Pharmacology. 340 (1): 45–51. doi:10.1007/bf00169206. PMID 2797214. S2CID 2287040.
Elliott JM, Kent A (July 1989). "Comparison of [125I]iodolysergic acid diethylamide binding in human frontal cortex and platelet tissue". Journal of Neurochemistry. 53 (1): 191–196. doi:10.1111/j.1471-4159.1989.tb07313.x. PMID 2723656. S2CID 25820829.
Schmuck K, Ullmer C, Kalkman HO, Probst A, Lubbert H (May 1996). "Activation of meningeal 5-HT2B receptors: an early step in the generation of migraine headache?". The European Journal of Neuroscience. 8 (5): 959–967. doi:10.1111/j.1460-9568.1996.tb01583.x. PMID 8743744. S2CID 19578349.
Barnes JM, Barnes NM, Costall B, Ironside JW, Naylor RJ (December 1989). "Identification and characterisation of 5-hydroxytryptamine 3 recognition sites in human brain tissue". Journal of Neurochemistry. 53 (6): 1787–1793. doi:10.1111/j.1471-4159.1989.tb09244.x. PMID 2809591. S2CID 46356673.
Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, et al. (March 1996). "Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding". Psychopharmacology. 124 (1–2): 57–73. doi:10.1007/bf02245606. PMID 8935801. S2CID 12028979.
Kanba S, Richelson E (June 1984). "Histamine H1 receptors in human brain labelled with [3H]doxepin". Brain Research. 304 (1): 1–7. doi:10.1016/0006-8993(84)90856-4. PMID 6146381. S2CID 45303586.
Kovachich GB, Aronson CE, Brunswick DJ, Frazer A (June 1988). "Quantitative autoradiography of serotonin uptake sites in rat brain using [3H]cyanoimipramine". Brain Research. 454 (1–2): 78–88. doi:10.1016/0006-8993(88)90805-0. PMID 2970277. S2CID 9586842.
Davids E, Lesch KP (November 1996). "[The 5-HT1A receptor: a new effective principle in psychopharmacologic therapy?]". Fortschritte der Neurologie-Psychiatrie (in German). 64 (11): 460–472. doi:10.1055/s-2007-996592. PMID 9064274. S2CID 147793142.
Desaphy JF, Pierno S, De Luca A, Didonna P, Camerino DC (March 2003). "Different ability of clenbuterol and salbutamol to block sodium channels predicts their therapeutic use in muscle excitability disorders" (PDF). Molecular Pharmacology. 63 (3): 659–670. doi:10.1124/mol.63.3.659. PMID 12606775. S2CID 631197. Archived from the original (PDF) on 20 February 2019.

pdfs.semanticscholar.org

Desaphy JF, Pierno S, De Luca A, Didonna P, Camerino DC (March 2003). "Different ability of clenbuterol and salbutamol to block sodium channels predicts their therapeutic use in muscle excitability disorders" (PDF). Molecular Pharmacology. 63 (3): 659–670. doi:10.1124/mol.63.3.659. PMID 12606775. S2CID 631197. Archived from the original (PDF) on 20 February 2019.

tabletwise.com

"Indoblok Tablet - Product - TabletWise.com". www.tabletwise.com. Retrieved 15 October 2022.

tga.gov.au

"Prescribing medicines in pregnancy database". Australian Government. 3 March 2014. Archived from the original on 8 April 2014. Retrieved 22 April 2014.

theguardian.com

Scott M (15 August 2008). "Olympics: North Korea's Kim Jong-su loses medals after positive drugs test". The Guardian. Guardian News and Media Limited. Retrieved 7 March 2018.

thieme-connect.com

Blaisdell GD (July 1994). "Akathisia: A Comprehensive Review and Treatment Summary". Pharmacopsychiatry. 27 (4): 139–146. doi:10.1055/s-2007-1014294. ISSN 0176-3679. PMID 7972345.

thieme-connect.de

Kornischka J, Cordes J, Agelink MW (April 2007). "40 years beta-adrenoceptor blockers in psychiatry". Fortschritte der Neurologie-Psychiatrie (in German). 75 (4): 199–210. doi:10.1055/s-2006-944295. PMID 17200914. S2CID 260156607.

unc.edu

pdsp.unc.edu

Roth BL, Driscol J. "PDSP K_i Database". Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Retrieved 14 August 2017.

web.archive.org

"Propranolol hydrochloride". Monograph. The American Society of Health-System Pharmacists. Archived from the original on 1 January 2015. Retrieved 1 January 2015.
Bryson PD (1997). Comprehensive review in toxicology for emergency clinicians (3 ed.). Washington, DC: Taylor & Francis. p. 167. ISBN 9781560326120. Archived from the original on 24 March 2017.
"Prescribing medicines in pregnancy database". Australian Government. 3 March 2014. Archived from the original on 8 April 2014. Retrieved 22 April 2014.
Briggs GG, Freeman RK, Yaffe SJ (2011). Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk (9th ed.). Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins. p. 1226. ISBN 9781608317080. Archived from the original on 14 February 2017.
"The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
Ladva S (28 June 2006). "NICE and BHS launch updated hypertension guideline". National Institute for Health and Clinical Excellence. Archived from the original on 24 September 2006. Retrieved 11 October 2009.
"Doctors test a drug to ease traumatic memories - Mental Health - NBC News". NBC News. Archived from the original on 12 November 2013. Retrieved 30 June 2007.
Eadie M, Tyrer JH (1985). The Biochemistry of Migraine. New York: Springer. p. 148. ISBN 9780852007310. OCLC 11726870. Archived from the original on 24 March 2017.
Desaphy JF, Pierno S, De Luca A, Didonna P, Camerino DC (March 2003). "Different ability of clenbuterol and salbutamol to block sodium channels predicts their therapeutic use in muscle excitability disorders" (PDF). Molecular Pharmacology. 63 (3): 659–670. doi:10.1124/mol.63.3.659. PMID 12606775. S2CID 631197. Archived from the original (PDF) on 20 February 2019.
Tim Glover. "Golf: O'Grady says players use beta-blockers: Drugs 'helped win majors'". The Independent. Archived from the original on 25 September 2015. Retrieved 28 March 2017.
"Hemangeol - Food and Drug Administration" (PDF). 1 March 2014. Archived (PDF) from the original on 2 April 2015. Retrieved 23 March 2015.

worldcat.org

search.worldcat.org

Blaisdell GD (July 1994). "Akathisia: A Comprehensive Review and Treatment Summary". Pharmacopsychiatry. 27 (4): 139–146. doi:10.1055/s-2007-1014294. ISSN 0176-3679. PMID 7972345.
Eadie M, Tyrer JH (1985). The Biochemistry of Migraine. New York: Springer. p. 148. ISBN 9780852007310. OCLC 11726870. Archived from the original on 24 March 2017.